Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd2066. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 known ✓ | P41594 | 9/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd2066 SCHEMBL29175535 | 1.00 | GRM5 (0.69) | GRM5KCNH2ALDH1A1NPC1RAB9A | |
| Azd2066 SCHEMBL4331565 | 0.95 | GRM5 (0.72) | GRM5KCNH2ALDH1A1NPC1RAB9A | |
| Azd2066 SCHEMBL1848325 | 0.95 | GRM5 (0.72) | GRM5KCNH2ALDH1A1NPC1RAB9A | |
| Azd2066 SCHEMBL1544607 | 0.95 | GRM5 (0.72) | GRM5KCNH2ALDH1A1NPC1RAB9A | |
| Azd2066 SCHEMBL5053440 | 0.94 | GRM5 (0.71) | GRM5KCNH2ALDH1A1NPC1RAB9A | |
| Azd2066 SCHEMBL4328931 | 0.94 | GRM5 (0.71) | GRM5KCNH2ALDH1A1NPC1RAB9A | |
| SCHEMBL4323911 | 0.86 | GRM5 (0.70) | GRM5KCNH2ALDH1A1NPC1RAB9A | |
| SCHEMBL5054869 | 0.86 | GRM5 (0.70) | GRM5KCNH2ALDH1A1NPC1RAB9A | |
| SCHEMBL2959556 | 0.82 | GRM5 (1.00) | GRM5KCNH2ALDH1A1NPC1RAB9A | |
| SCHEMBL2967887 | 0.82 | GRM5 (1.00) | GRM5KCNH2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476684-B2 | Compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2009-01-13 | — | — | US | claimed |
| US-20080227824-A1 | 5-(Phenylisoxazolylethoxy) - Triazol- 3 -Yl Substituted Pyridine Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | claimed |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | claimed |
| CN-114599649-B | Compounds for preventing and/or treating excessive fatigue in mammals | 克拉斯·图林 | 2024-07-12 | — | — | CN | disclosed |
| CN-113811297-B | 4- [5- [ (rac) -1- [5- (3-chlorophenyl) -3-isoxazolyl ] ethoxy ] -4-methyl-4H-1, 2, 4-triazol-3-yl ] pyridine for use in the prevention and/or treatment of pain in animals | 克拉斯·图林 | 2024-03-26 | — | — | CN | disclosed |
| CN-114599649-A | 4- [5- [ (rac) -1- [5- (3-chlorophenyl) -3-isoxazolyl ] ethoxy ] -4-methyl-4H-1, 2, 4-triazol-3-yl ] pyridine for the prevention and/or treatment of hyper-fatigue in mammals | 克拉斯·图林 | 2022-06-07 | — | — | CN | disclosed |
| CN-113811297-A | 4- [5- [ (rac) -1- [5- (3-chlorophenyl) -3-isoxazolyl ] ethoxy ] -4-methyl-4H-1, 2, 4-triazol-3-yl ] pyridine for the prevention and/or treatment of pain in an animal | 克拉斯·图林 | 2021-12-17 | — | — | CN | disclosed |
| US-7476684-B2 | Compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2009-01-13 | — | — | US | disclosed |
| US-20080227824-A1 | 5-(Phenylisoxazolylethoxy) - Triazol- 3 -Yl Substituted Pyridine Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-20070270468-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270469-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270469-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | GRIN2C, OPRL1, GRIN2A | GRM5 17/4885KCNH2 579/4885ALDH1A1 1996/4885 |
| US-20080227824-A1 | 5-(Phenylisoxazolylethoxy) - Triazol- 3 -Yl Substituted Pyridine Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders | GRIN2C, GRIK5, GRIN3A | GRM5 13/4885KCNH2 331/4885ALDH1A1 1035/4885 |
| US-20070270468-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | GRIN2C, OPRL1, GRIN2A | GRM5 17/4885KCNH2 579/4885ALDH1A1 1996/4885 |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | GRIN2C, OPRL1, GRIN2A | GRM5 17/4885KCNH2 579/4885ALDH1A1 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.